Growth hormone modulation of arginine-induced glucagon release: studies of isolated growth hormone deficiency and acromegaly. 1978

Y Seino, and T Taminato, and Y Goto, and Y Inoue, and S Kadowaki, and M Hattori, and K Mori, and Y Kato, and S Matsukura, and H Imura

Plasma glucagon and insulin responses to L-arginine were compared in normal controls and patients with isolated growth hormone deficiency and acromegaly. Patients with isolated growth hormone deficiency were characterized by high plasma glucagon response and low plasma insulin response, whereas acromegalic patients showed exaggerated plasma glucagon response and almost normal insulin response. These results suggest that growth hormone is probably required for optimum function of the islets, and since hyperglucagonaemia was observed in both growth hormone deficiency and acromegaly, metabolic disturbances stemming from the respective primary diseases may affect glucagon secretion.

UI MeSH Term Description Entries
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D001786 Blood Glucose Glucose in blood. Blood Sugar,Glucose, Blood,Sugar, Blood
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D003920 Diabetes Mellitus A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.
D005260 Female Females
D005934 Glucagon A 29-amino acid pancreatic peptide derived from proglucagon which is also the precursor of intestinal GLUCAGON-LIKE PEPTIDES. Glucagon is secreted by PANCREATIC ALPHA CELLS and plays an important role in regulation of BLOOD GLUCOSE concentration, ketone metabolism, and several other biochemical and physiological processes. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1511) Glucagon (1-29),Glukagon,HG-Factor,Hyperglycemic-Glycogenolytic Factor,Proglucagon (33-61),HG Factor,Hyperglycemic Glycogenolytic Factor
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000172 Acromegaly A condition caused by prolonged exposure to excessive HUMAN GROWTH HORMONE in adults. It is characterized by bony enlargement of the FACE; lower jaw (PROGNATHISM); hands; FEET; HEAD; and THORAX. The most common etiology is a GROWTH HORMONE-SECRETING PITUITARY ADENOMA. (From Joynt, Clinical Neurology, 1992, Ch36, pp79-80) Inappropriate Growth Hormone Secretion Syndrome (Acromegaly),Somatotropin Hypersecretion Syndrome (Acromegaly),Inappropriate GH Secretion Syndrome (Acromegaly),Hypersecretion Syndrome, Somatotropin (Acromegaly),Hypersecretion Syndromes, Somatotropin (Acromegaly),Somatotropin Hypersecretion Syndromes (Acromegaly),Syndrome, Somatotropin Hypersecretion (Acromegaly),Syndromes, Somatotropin Hypersecretion (Acromegaly)

Related Publications

Y Seino, and T Taminato, and Y Goto, and Y Inoue, and S Kadowaki, and M Hattori, and K Mori, and Y Kato, and S Matsukura, and H Imura
October 1970, Acta endocrinologica,
Y Seino, and T Taminato, and Y Goto, and Y Inoue, and S Kadowaki, and M Hattori, and K Mori, and Y Kato, and S Matsukura, and H Imura
September 1988, Postgraduate medical journal,
Y Seino, and T Taminato, and Y Goto, and Y Inoue, and S Kadowaki, and M Hattori, and K Mori, and Y Kato, and S Matsukura, and H Imura
June 1983, The Journal of clinical endocrinology and metabolism,
Y Seino, and T Taminato, and Y Goto, and Y Inoue, and S Kadowaki, and M Hattori, and K Mori, and Y Kato, and S Matsukura, and H Imura
October 1983, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme,
Y Seino, and T Taminato, and Y Goto, and Y Inoue, and S Kadowaki, and M Hattori, and K Mori, and Y Kato, and S Matsukura, and H Imura
March 1974, British medical journal,
Y Seino, and T Taminato, and Y Goto, and Y Inoue, and S Kadowaki, and M Hattori, and K Mori, and Y Kato, and S Matsukura, and H Imura
August 1969, The Journal of clinical endocrinology and metabolism,
Y Seino, and T Taminato, and Y Goto, and Y Inoue, and S Kadowaki, and M Hattori, and K Mori, and Y Kato, and S Matsukura, and H Imura
September 1984, Research communications in chemical pathology and pharmacology,
Y Seino, and T Taminato, and Y Goto, and Y Inoue, and S Kadowaki, and M Hattori, and K Mori, and Y Kato, and S Matsukura, and H Imura
July 1981, Metabolism: clinical and experimental,
Y Seino, and T Taminato, and Y Goto, and Y Inoue, and S Kadowaki, and M Hattori, and K Mori, and Y Kato, and S Matsukura, and H Imura
January 2015, Trends in endocrinology and metabolism: TEM,
Y Seino, and T Taminato, and Y Goto, and Y Inoue, and S Kadowaki, and M Hattori, and K Mori, and Y Kato, and S Matsukura, and H Imura
August 1970, The Journal of clinical endocrinology and metabolism,
Copied contents to your clipboard!